“Ultimovacs går nå i gang med en fase 2 studie som skal undersøke effekten av å legge kreftvaksinen UV1 til […]
Other News |
Press Releases
BioStock has published the article: “Ultimovacs initiates fourth phase II trial with UV1”
“Christmas came a few days early for Ultimovacs as the company was able to announce the initiation of its fourth […]
Ticker on Oslo Børs changed to ULTI
The company ticker on Oslo Børs has now changed from ULTIMO to ULTI.
Full version of the publication in ‘Frontiers in Immunology’ featuring positive results from Phase I trial evaluating UV1 in Non-Small Cell Lung Cancer is now available
In referanse to the Stock Exchange announcement on 2 November 2020 (below) where an abstract of the publication was available. […]
BioStock has done a piece on Ultimovacs’ main advancements in the Q3-2020 period
“Ultimovacs is developing a universal cancer vaccine with the aim of inducing an immune response in cancer patients that is […]
Interview with Carlos de Sousa in Nordic Life Science magazine
“In June this year, Carlos de Sousa commenced his role as Chief Executive Officer of Norwegian Ultimovacs, a pharmaceutical company […]
Sara Mangsbo recieves 2020 SITC Team Science Award
As SITC celebrates 35 years of advancing the field of cancer immunotherapy, they want to recognize and honor those that […]
BioStock has published the article: “Ultimovacs in the fight against Melanoma”
“Melanoma is the deadliest form of skin cancer. As such, new treatments for the disease are in strong demand. Norwegian […]
Article in HealthTalk covering the Topline Results from Phase I Combination Trial Evaluating Universal Cancer Vaccine, UV1, in Malignant Melanoma Patients
“Ultimovacs med lovende overlevelsesdata på pasienter med føflekkreft som fikk kreftvaksinen UV1 i kombinasjon med immunterapi Ultimovacs har nå gått […]
BioStock has published an in-depth article on Ultimovacs
“Cancer’s heavy burden on society has created a strong demand for new innovative therapeutic solutions. Over the last decade, immunotherapy […]